MetaVia To Present Vanoglipel Data For MASH At AASLD, Highlighting Hepatoprotective And Metabolic Effects

Author: Benzinga Newsdesk | October 27, 2025 08:43am

MetaVia Inc. (NASDAQ:MTVA), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced that an abstract highlighting data on Vanoglipel (DA-1241), a novel G-Protein-Coupled Receptor 119 (GPR119) agonist, has been accepted for a poster presentation at the American Association for the Study of Liver Diseases (AASLD) Liver Meeting 2025, taking place November 7-11, 2025 in Washington, D.C.

• Title: Vanoglipel (DA-1241), a GPR119 Agonist, Demonstrates Hepatoprotective Effects Through Improving Inflammation and Metabolism in the Liver: A 16-week Randomized Placebo-Controlled Trial in Presumed MASH Patients
• Presenting Author: Rohit Loomba, M.D., MHSc, Professor of Medicine, Chief, Division of Gastroenterology and Hepatology at the University of California at San Diego.
• Poster Number: 4012
• Session: Monday Poster Presenters Hall Hour
• Poster Date: Monday, November 10, 2025
• Poster Time: 1:00-2:00 pm ET
• Poster Location: Convention Center: Hall DE (Posters & Exhibits), Level 2

A copy of the poster will be available on the Posters section of the MetaVia website after the presentation.

About Vanoglipel (DA-1241)

Vanoglipel (DA-1241) is a novel G-Protein-Coupled Receptor 119 (GPR119) agonist with development optionality as a standalone and/or combination therapy for both MASH and type 2 diabetes (T2D). Agonism of GPR119 in the gut promotes the release of key gut peptides GLP-1, GIP, and PYY. These peptides play a further role in glucose metabolism, lipid metabolism and weight loss. DA-1241 has beneficial effects on glucose, lipid profile and liver inflammation, supported by potential efficacy demonstrated during in vivo preclinical studies. The therapeutic potential of DA-1241 has been demonstrated in multiple pre-clinical animal models of MASH and T2D where DA-1241 reduced hepatic steatosis, inflammation, fibrosis, and improved glucose control. Furthermore, in Phase 1a, 1b and 2a trials, DA-1241 was well tolerated in both healthy volunteers and those with T2DM. In a Phase 2a clinical study, DA-1241 demonstrated direct hepatic action in addition to its glucose lowering effects.

Posted In: MTVA